• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ovid Therapeutics Inc (NQ: OVID )

    1.169 +0.019 (+1.66%)
    Streaming Delayed Price Updated: 3:35 PM EDT, Oct 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 34,907
    Open 1.150
    Bid (Size) 1.160 (10)
    Ask (Size) 1.170 (10)
    Prev. Close 1.150
    Today's Range 1.150 - 1.190
    52wk Range 0.6800 - 4.100
    Shares Outstanding 70,417,345
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
    From Ovid Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    -64.79%
    -64.79%
    1 Month
    -0.08%
    -0.08%
    3 Month
    +12.41%
    +12.41%
    6 Month
    -63.12%
    -63.12%
    1 Year
    -69.07%
    -69.07%

    More News

    Read More
    Ovid Therapeutics to Present at Upcoming September Investor Conferences
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
    Via Benzinga
    The Latest Analyst Ratings For Ovid Therapeutics
    Via Benzinga
    Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
    Via Benzinga
    OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    Ovid Therapeutics to Present at Upcoming August Investor Conferences
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    7 Sorry Biotech Stocks Set to Make Investors Sad
    Via InvestorPlace
    eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Nasdaq Surges Over 200 Points; Aaron's Shares Jump
    Via Benzinga
    Is the Stock Market Closed on Juneteenth 2024?
    Via InvestorPlace
    ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
    Via InvestorPlace
    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
    Via InvestorPlace
    Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    US Stocks Mixed; Dow Tumbles Over 100 Points
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.